Sweden

In October of 2018, the Dental and Pharmaceutical Benefits Agency (TLV) has published a completed health economic evaluation regarding the clinical efficacy and cost-effectiveness MiniMed 670G in comparison to MiniMed 640G device. TLV concluded that the use of the MiniMed 670G can increase the patients’ quality of life due to reduced concern for hypoglycemia, increased comfort, fewer complications and also lead to potential cost benefits.

In July of 2018, the Dental and Pharmaceutical Benefits Agency (Tandvårds-Läkemedelförmånsverket, TLV) has updated the product group codes for consumables for better understanding the range of the products. Editorial changes to the codes' descriptions were implemented. Seven new groups for stomach products, plates and bags of different types, which are especially intended for children have been included in the classification.

At the end of June of 2018, the National Board of Health and Welfare (Socialtyrelsen) has published an updated version of the National clinical guidelines for heart care. The review was conducted for the inclusion of few updated recommendations regarding the management of the coronary heart disease, valvulopathy and arrhythmia.

On the 5th of June of 2018, Dental and Pharmaceutical Benefit Agency (Tandvårds- och läkemedelsförmånsverket, TLV) has published a decision regarding inclusion of number of Verifine blood lancets produced by Mediq Sverige AB for diabetic patients to monitor the blood glucose levels into the list of pharmaceutical benefits with the price of SEK 23 per package.

On the 14th of May of 2018, Dental and Pharmaceutical Benefit Agency (Tandvårds- och läkemedelsförmånsverket, TLV) has published a decision regarding inclusion of number of consumable medical devices for the treatment of asthma and chronic obstructive pulmonary disease (COPD) into the list of pharmaceutical benefits with the price of SEK 236.35 per piece.

In April of 2018, Dental and Pharmaceutical Benefit Agency (Tandvårds- och läkemedelsförmånsverket, TLV) has published a number of consumable medical devices, which were excluded from the list of pharmaceutical benefits per manufacturers’ request.

On the 26th of April of 2018, Dental and Pharmaceutical Benefit Agency (Tandvårds- och läkemedelsförmånsverket, TLV) has published a positive decision for inclusion of Aurum Convex (one-piece range of colostomy, ileostomy and urostomy bags with Manuka honey) into the list of pharmaceutical benefits with the price of its comparators of 48.13 SEK per product.

In April of 2018, the National Board of Health and Welfare (Socialstyrelsen) has published a report “Screening for severe combined immune deficiency”, which contains recommendation and assessment basis for the national combined immunodeficiency screening program (SCID).

On the 5th of April of 2018, Dental and Pharmaceutical Benefit Agency (Tandvårds- och läkemedelsförmånsverket, TLV) has published a positive decision for inclusion of VORTEX nozzle (spare part for VORTEX inhalation container) into the list of pharmaceutical benefits due to lower price of 45.42 SEK per product versus comparators.

On the 16th of April, 2018, the new classification of diagnosis codes (ICD-10-SE) was released by the National Board of Health and Welfare (Socialstyrelsen). Seventeen new diagnosis codes were added in 2018.

In February of 2018, Dental and Pharmaceutical Benefit Agency (Tandvårds- och läkemedelsförmånsverket, TLV) has published a number of consumable medical devices, which were excluded from the list of pharmaceutical benefits per manufacturers’ request.

At the beginning of March, 2018, the National Board of Health and Welfare (Socialtyrelsen) has published the instruction with the amendments for coding of infected wounds. Several clarifications to the use of these diagnosis codes were implemented.